Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases
Open Access
- 30 April 2015
- journal article
- case report
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (2) , 2757-2764
Abstract
Psoriasis, a chronic inflammatory skin disease, is caused by infiltrating lymphocytes and associated cytokines, including tumor necrosis factor (TNF)α, interleukin (IL)-6, and IL-17. Effective treatments, including pathogenesis-based biological agents against psoriasis, are currently under development. Although the role of reactive oxygen species (ROS) in the pathogenesis of psoriasis has been investigated, it remains to be fully elucidated; ROS-targeted therapeutic strategies are also lacking at present. Therefore, the objective of the present study was to assess whether H2, a ROS scavenger, has a therapeutic effect on psoriasis-associated inflammation by reducing hydroxyl radicals or peroxynitrite in the immunogenic psoriasis cascade. Three methods were used to administer H2: Drop infusion of saline containing 1 ppm H2 (H2-saline), inhalation of 3% H2 gas, and drinking of water containing a high concentration (5-7-ppm) of H2 (high-H2 water). Treatment efficacy was estimated using the disease activity score 28 (DAS28) system, based on C-reactive protein levels, and the psoriasis area and severity index (PASI) score, determined at baseline and following each H2 treatment. Furthermore, levels of TNFα, IL-6, and IL-17 were analyzed. The DAS28 and PASI score of the three patients decreased during H2 treatment, regardless of the administration method. The psoriatic skin lesions almost disappeared at the end of the treatment. IL-6 levels decreased during H2 treatment in Case 1 and 2. IL-17, whose concentration was high in Case 1, was reduced following H2 treatment, and TNFα also decreased in Case 1. In conclusion, H2 administration reduced inflammation associated with psoriasis in the three cases examined and it may therefore be considered as a treatment strategy for psoriasis-associated skin lesions and arthritis.Keywords
This publication has 31 references indexed in Scilit:
- The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical FindingsJournal of Investigative Dermatology, 2013
- Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—A possible target for novel therapies?Journal of Dermatological Science, 2010
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T CellsThe Journal of Immunology, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic managementBritish Journal of Dermatology, 2008
- PsoriasisNew England Journal of Medicine, 2005
- Serum Levels of TNF‐α, IFN‐γ, IL‐6, IL‐8,IL‐12, IL‐17, and IL‐18 in Patients With Active Psoriasis andCorrelation With Disease SeverityMediators of Inflammation, 2005
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatmentsJournal of Dermatological Science, 1997